Regeneron's Odronextamab Receives Opinion from EMA for Lymphoma Treatment
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals announced that the EMA's CHMP has adopted a positive opinion recommending conditional marketing authorization of odronextamab for treating relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The final decision by the European Commission is expected in the coming months.
June 28, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals received a positive opinion from the EMA's CHMP for conditional marketing authorization of odronextamab for treating relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The final decision by the European Commission is expected in the coming months.
The positive opinion from the EMA's CHMP is a significant step towards the conditional marketing authorization of odronextamab, which could lead to increased revenue for Regeneron if approved. The final decision by the European Commission will be crucial.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100